Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2

Molecular Pharmacology

Volumn 86, Issue 4, 2014, Pages 358-368

  Zweemer, Annelien J M ^a   Bunnik, Julia ^a   Veenhuizen, Margo ^a   Miraglia, Fabiana ^a   Lenselink, Eelke B ^a   Vilums, Maris ^a   De Vries, Henk ^a   Gibert, Arthur ^a   Thiele, Stefanie ^b   Rosenkilde, Mette M ^b   IJzerman, Adriaan P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; G PROTEIN COUPLED RECEPTOR; JNJ 27141491; N [2 [[1 [4 (1,3 BENZODIOXOL 5 YL) 4 HYDROXYCYCLOHEXYL] 4 ETHOXY 3 PYRROLIDINYL]AMINO] 2 OXOETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; PHENYLALANINE; SD 24; TYROSINE; UNCLASSIFIED DRUG; CCR2 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; JNJ-27141491; LIGAND; PYRROLIDINE DERIVATIVE; SULFONAMIDE;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; COS 7 CELL LINE; DRUG RECEPTOR BINDING; IC50; LIGAND BINDING; MOLECULAR DOCKING; POINT MUTATION; SEQUENCE ALIGNMENT; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; CHO CELL LINE; COS 1 CELL LINE; CRICETULUS; DRUG ANTAGONISM; GENETICS; HAMSTER; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN MOTIF; TUMOR CELL LINE;

ALLOSTERIC SITE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; HUMANS; IMIDAZOLES; LIGANDS; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, CCR2; SULFONAMIDES;

EID: 84907918101     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.093328     Document Type: Article

References (49)

1. Andrews G, Jones C, and Wreggett KA (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73:855-867.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods in Neurosciences 25:366-428.
3. Boring L, Gosling J, Cleary M, and Charo IF (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897.
4. Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, and Collier P et al. (2005) Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 175:5370-5378.
5. de Kruijf P, van Heteren J, Lim HD, Conti PG, van der Lee MM, Bosch L, Ho KK, Auld D, Ohlmeyer M, and Smit MJ et al. (2009) Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor. J Pharmacol Exp Ther 329:783-790.
6. De Lean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled betaadrenergic receptor. J Biol Chem 255:7108-7117.
7. Dowal L, Sim DS, Dilks JR, Blair P, Beaudry S, Denker BM, Koukos G, Kuliopulos A, and Flaumenhaft R (2011) Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc Natl Acad Sci USA 108:2951-2956.
8. Doyon J, Coesemans E, Boeckx S, Buntinx M, Hermans B, Van Wauwe JP, Gilissen RA, De Groot AH, Corens D, and Van Lommen G (2008) Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor. Chem-MedChem 3:660-669.
9. Fantuzzi L, Borghi P, Ciolli V, Pavlakis G, Belardelli F, and Gessani S (1999) Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secretedMCP-1 in the regulation of the chemotactic response. Blood 94:875-883.
10. Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, and Ernst OP (2003) Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 100:2290-2295.
11. Furchgott RF (1964) Receptor mechanisms. Annu Rev Pharmacol 4:21-50.
12. Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, Kanjanapangka J, Harirchian P, Chen D, and Selchau V et al. (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 75:1325-1336.
13. Hulme EC (2013) GPCR activation: a mutagenic spotlight on crystal structures. Trends Pharmacol Sci 34:67-84.
14. Jacobson MP, Friesner RA, Xiang Z, and Honig B (2002) On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 320: 597-608.
15. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, and Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins 55: 351-367.
16. Jensen PC, Thiele S, Steen A, Elder A, Kolbeck R, Ghosh S, Frimurer TM, and Rosenkilde MM (2012) Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2. Br J Pharmacol 166:258-275.
17. Jimenez F, Quinones MP, Martinez HG, Estrada CA, Clark K, Garavito E, Ibarra J, Melby PC, and Ahuja SS (2010) CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B. J Immunol 184:5571-5581.
18. Kalatskaya I, Schüssler S, Blaukat A, Müller-Esterl W, Jochum M, Proud D, and Faussner A (2004) Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B2 bradykinin receptor. J Biol Chem 279:31268-31276.
19. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
20. Kissow H, Hartmann B, Holst JJ, Viby NE, Hansen LS, Rosenkilde MM, Hare KJ, and Poulsen SS (2012) Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 179: 91-100.
21. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, and Sexton PM et al. (2013) Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504:101-106.
22. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G proteincoupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
23. Luster AD (1998) Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 338:436-445.
24. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, and Arnold GF et al. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281:12688-12698.
25. Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, and Mitsuya H (2008) Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 381: 956-974.
26. Mahad DJ and Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15:23-32.
27. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, and Dankwardt J et al. (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275: 25562-25571.
28. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, and Wright TJ et al. (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74:1193-1202.
29. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, and Schwartz TW (2009) Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 249-259.
30. Peace S, Philp J, Brooks C, Piercy V, Moores K, Smethurst C, Watson S, Gaines S, Zippoli M, and Mookherjee C et al. (2010) Identification of a sulfonamide series of CCR2 antagonists. Bioorg Med Chem Lett 20:3961-3964.
31. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, and Ahuja SS (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med (Berl) 83:672-681.
32. Rosenkilde MM, Benned-Jensen T, Frimurer TM, and Schwartz TW (2010) The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol Sci 31:567-574.
33. Rosenkilde MM and Schwartz TW (2006) GluVII:06 - a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6:1319-1333.
34. Salchow K, Bond ME, Evans SC, Press NJ, Charlton SJ, Hunt PA, and Bradley ME (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159:1429-1439.
35. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, and Leurs R (2012) Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165:1617-1643.
36. Sherman W, Beard HS, and Farid R (2006) Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des 67:83-84.
37. Shields DC (2000) Gene conversion among chemokine receptors. Gene 246:239-245.
38. Shin N, Baribaud F, Wang K, Yang G, Wynn R, Covington MB, Feldman P, Gallagher KB, Leffet LM, and Lo YY et al. (2009) Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem Biophys Res Commun 387:251-255.
39. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
40. Surgand JS, Rodrigo J, Kellenberger E, and Rognan D (2006) A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62:509-538.
41. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, and Li J et al. (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science 341:1387-1390.
42. Thiele S, Steen A, Jensen PC, Mokrosinski J, Frimurer TM, and Rosenkilde MM (2011) Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach. J Biol Chem 286:37543-37554.
43. Toda E, Terashima Y, Sato T, Hirose K, Kanegasaki S, and Matsushima K (2009) FROUNT is a common regulator of CCR2 and CCR5 signaling to control directional migration. J Immunol 183:6387-6394.
44. White FA, Bhangoo SK, and Miller RJ (2005) Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov 4:834-844.
45. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644.
46. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, and Bi FC et al. (2010) Structures of the CXCR4 chemokine GPCR with smallmolecule and cyclic peptide antagonists. Science 330:1066-1071.
47. Xue CB, Metcalf B, Feng H, Cao G, Huang T, Zheng C, Robinson D, and Han A (2004) inventors, Incyte Corporation, assignee. 3-Aminopyrrolidine derivatives as modulators of chemokine receptors. Patent PCT/US2003/037946. 2004 Jun 17.
48. Zou D, Zhai HX, Eckman J, Higgins P, Gillard M, Knerr L, Carre S, Pasau P, Collart P, and Grassi J et al. (2007) Novel, acidic CCR2 receptor antagonists: from hit to lead. Lett Drug Des Discov 4:185-191.
49. Zweemer AJM, Nederpelt I, Vrieling H, Hafith S, Doornbos ML, de Vries H, Abt J, Gross R, Stamos D, and Saunders J et al. (2013) Multiple binding sites for smallmolecule antagonists at the CC chemokine receptor 2. Mol Pharmacol 84:551-561.